About Verrica Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://verrica.com/
Frequently Asked Questions
What is the 52-week range for VRCA?
The 52-week high is $9.821 and the 52-week low is $3.28.
What is the P/E ratio for VRCA?
The P/E ratio data is currently unavailable.
What is the dividend yield for VRCA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -205.58%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -102.84%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.19.
Analyst Recommendation Trends
Wall Street analyst consensus for VRCA over the last few months:
Latest VRCA News
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration – WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on YCANTH® (VP-102), a therapy approved by the FDA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference. H.C. Wainwright 28th Annual Global Investment ConferenceEvent d
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-18 | Rosenberg Noah L. | +2,030 | $4.92 | $9,988 |
| 2026-08-18 | Kirby John J. | +5,000 | $4.93 | $24,650 |
| 2026-08-17 | Zawitz David | +6,000 | $4.98 | $29,880 |
| 2026-08-17 | Rieger Jayson | +5,000 | $4.91 | $24,550 |
| 2026-08-17 | Rosenberg Noah L. | +4,200 | $4.91 | $20,622 |
| 2026-08-14 | Rieger Jayson | +20,000 | $5.06 | $101,200 |
| 2026-06-05 | Zawitz David | +171,340 | - | - |
| 2026-06-05 | Rieger Jayson | +512,269 | - | - |
| 2026-06-05 | Eichenfield Lawrence | +16,000 | - | - |
| 2026-06-05 | Nguyen Diem | +16,000 | - | - |
| 2026-06-05 | Corcoran Gavin | +16,000 | - | - |
| 2026-06-05 | Rosenberg Noah L. | +233,840 | - | - |
| 2026-06-05 | PRYGOCKI MARK A SR | +16,000 | - | - |
| 2025-12-23 | Kirby John J. | +10,000 | - | - |
| 2025-11-25 | Zawitz David | +2,500 | - | - |
| 2025-11-25 | Zawitz David | +10,000 | $4.2425 | $42,425 |
| 2025-11-25 | Rieger Jayson | +23,577 | - | - |
| 2025-11-25 | Rieger Jayson | +94,311 | $4.2425 | $400,114 |
| 2025-11-25 | Rosenberg Noah L. | +589 | - | - |
| 2025-11-25 | Rosenberg Noah L. | +2,357 | $4.2425 | $10,000 |
| 2025-11-25 | Kirby John J. | +884 | - | - |
| 2025-11-25 | Kirby John J. | +3,536 | $4.2425 | $15,001 |
| 2025-11-25 | Manning Paul B | +687,690 | - | - |
| 2025-11-25 | Manning Paul B | +343,845 | - | - |
| 2025-11-25 | Manning Paul B | +2,750,762 | $4.2425 | $11,670,108 |
| 2025-11-25 | Manning Paul B | +1,375,380 | $4.2425 | $5,835,050 |